Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A pilot safety and immunogenicity trial of the malaria vaccine SPf66 has been undertaken in 150 Gambian infants. No significant systemic side effects were recorded but modest local reactions were seen after the administration of a third 1.0 mg dose. SPf66 produced in Colombia was more immunogenic than SPf66 produced in the USA and a 1.0 mg dose of each vaccine gave higher antibody levels than a 0.5 mg dose. However, antibody levels fell rapidly after administration of the third dose of vaccine and showed little change over the following malaria transmission season. The incidence of clinical malaria was higher among children who received SPf66 than among children who received inactivated polio vaccine, the effect being most marked among children who received 1.0 mg Colombian SPf66. As the trial was not designed to measure the effect of SPf66 on morbidity from malaria, the significance of this finding is uncertain.

Original publication

DOI

10.1111/j.1365-3024.1995.tb00912.x

Type

Journal article

Journal

Parasite immunology

Publication Date

08/1995

Volume

17

Pages

441 - 444

Addresses

MRC Laboratories, Fajara, Banjul, The Gambia.

Keywords

Animals, Humans, Plasmodium falciparum, Malaria, Falciparum, Malaria Vaccines, Antibodies, Protozoan, Immunization, Pilot Projects, Infant, Gambia, Female, Male